These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 19237713)

  • 1. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
    Chamberlain MC
    Neurology; 2009 Feb; 72(8):772-3; author reply 773-4. PubMed ID: 19237713
    [No Abstract]   [Full Text] [Related]  

  • 2. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
    Mrugala MM
    Neurology; 2009 Feb; 72(8):773; author reply 773-4. PubMed ID: 19248218
    [No Abstract]   [Full Text] [Related]  

  • 3. 10 Questions about the use of bevacizumab in the management of recurrent malignant gliomas.
    Chamberlain MC
    Neurologist; 2010 Jan; 16(1):56-60. PubMed ID: 20065801
    [No Abstract]   [Full Text] [Related]  

  • 4. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
    Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
    Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas.
    Chamberlain MC
    Cancer; 2010 Sep; 116(17):3988-99. PubMed ID: 20564141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab and recurrent malignant gliomas: a European perspective.
    Wick W; Weller M; van den Bent M; Stupp R
    J Clin Oncol; 2010 Apr; 28(12):e188-9; author reply e190-2. PubMed ID: 20159801
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas.
    Hwang EI; Jakacki RI; Fisher MJ; Kilburn LB; Horn M; Vezina G; Rood BR; Packer RJ
    Pediatr Blood Cancer; 2013 May; 60(5):776-82. PubMed ID: 22976922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival.
    Narayana A; Kelly P; Golfinos J; Parker E; Johnson G; Knopp E; Zagzag D; Fischer I; Raza S; Medabalmi P; Eagan P; Gruber ML
    J Neurosurg; 2009 Jan; 110(1):173-80. PubMed ID: 18834263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab for the treatment of high-grade glioma.
    Khasraw M; Simeonovic M; Grommes C
    Expert Opin Biol Ther; 2012 Aug; 12(8):1101-11. PubMed ID: 22663137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New agents and new end points for recurrent gliomas.
    Brandes AA; Franceschi E
    J Clin Oncol; 2011 Mar; 29(9):e245-6; author reply e247. PubMed ID: 21282544
    [No Abstract]   [Full Text] [Related]  

  • 11. Bevacizumab induced reversible thrombocytopenia in a patient with recurrent high-grade glioma: a case report.
    Leal T; Robins HI
    Cancer Chemother Pharmacol; 2010 Jan; 65(2):399-401. PubMed ID: 19756604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Angiogenesis suppressing therapy applied to malignant glioma].
    Takano S
    Gan To Kagaku Ryoho; 2009 Jun; 36(6):941-7. PubMed ID: 19579331
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Clinical article.
    Boockvar JA; Tsiouris AJ; Hofstetter CP; Kovanlikaya I; Fralin S; Kesavabhotla K; Seedial SM; Pannullo SC; Schwartz TH; Stieg P; Zimmerman RD; Knopman J; Scheff RJ; Christos P; Vallabhajosula S; Riina HA
    J Neurosurg; 2011 Mar; 114(3):624-32. PubMed ID: 20964595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of failure of bevacizumab treatment for malignant glioma based on urinary matrix metalloproteinase activity.
    Takano S; Mashiko R; Osuka S; Ishikawa E; Ohneda O; Matsumura A
    Brain Tumor Pathol; 2010 Oct; 27(2):89-94. PubMed ID: 21046310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab does not increase the risk of remote relapse in malignant glioma.
    Wick A; Dörner N; Schäfer N; Hofer S; Heiland S; Schemmer D; Platten M; Weller M; Bendszus M; Wick W
    Ann Neurol; 2011 Mar; 69(3):586-92. PubMed ID: 21446027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. D-dimer elevation and paresis predict thromboembolic events during bevacizumab therapy for recurrent malignant glioma.
    Misch M; Czabanka M; Dengler J; Stoffels M; Auf G; Vajkoczy P; Stockhammer F
    Anticancer Res; 2013 May; 33(5):2093-8. PubMed ID: 23645760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy for recurrent malignant glioma in adults.
    Mrugala MM; Kesari S; Ramakrishna N; Wen PY
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):759-82. PubMed ID: 15485312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab and irinotecan for recurrent oligodendroglial tumors.
    Chamberlain MC
    Neurology; 2010 Jan; 74(2):181. PubMed ID: 20065257
    [No Abstract]   [Full Text] [Related]  

  • 19. Avastin: more questions than answers. .
    Desjardins A; Sampson JH
    J Neurosurg; 2012 Feb; 116(2):336-40; discussion 340. PubMed ID: 22035270
    [No Abstract]   [Full Text] [Related]  

  • 20. Bevacizumab for recurrent hemangioendothelioma.
    Trautmann K; Bethke A; Ehninger G; Folprecht G
    Acta Oncol; 2011 Jan; 50(1):153-4. PubMed ID: 20950228
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.